A #perioperative regimen for muscle-invasive #bladdercancer (MIBC) based on AstraZeneca's Imfinzi and Astellas/Pfizer's Padcev has improved survival in the #VOLGAstudy, but the jury is out on whether it will displace a rival, established alternative.

pharmaphorum.com/news/esmo26-...